Physiomics PLC Contract Award
October 17 2024 - 2:00AM
RNS Regulatory News
RNS Number : 4715I
Physiomics PLC
17 October 2024
17 October 2024
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce that it has been awarded
a new contract by an existing client Cancer Research UK. The
project involves the development of Pharmacokinetic Pharmacodynamic
(PK/PD)* model to simulate the exposure-response relationship for a
novel oncology therapy to guide starting dose and dose range for an
upcoming First in Human Study.
Dr Peter
Sargent, CEO, commented: "We are delighted to have been awarded this
new contract with one of our existing clients. This contract
reflects the impact of the services we provide and our continued
relationship with Cancer Research UK".
* PKPD modelling is a scientific approach used
to describe and predict the relationship between drug concentration
in the body (PK) and the corresponding biological or physiological
effect (PD). This supports the prediction of what the optimum drug
dose needs to be to enable a therapeutic effect whilst minimising
levels of toxicity.
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Limited (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
CNTGPGWWUUPCGWQ
Physiomics (LSE:PYC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From Nov 2023 to Nov 2024